Beijing Kanglisheng Pharm Tech Development Co. Ltd.

Primary objective: To study the relative bioavailability of 15 mg Dacomitinib Tablets (Dacomitinib Tablets/ Vizimpro®/ DuoZhenrun®) (reference preparation) of Beijing Kanglisheng Pharmaceutical Technology Development Co., Ltd. and Pfizer Limited/Europe MA EEIG (Dacomitinib Tablets/ Vizimpro®/ DuoZhenrun®) (reference preparation) in healthy subjects in the fasting/postprandial state after a single oral administration, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To observe the safety and tolerability of the test preparation and the reference preparation in healthy Chinese subjects through changes in adverse event incidence, laboratory test results, vital signs and physical examinations.

Primary objective: To study the relative bioavailability of a single oral dose of 20 mg vonoprazan fumarate tablets (test preparation) of Beijing Kanglisheng Pharmaceutical Technology Development Co., Ltd. and 20 mg vonoprazan fumarate tablets (Vonoprazan Fumarate Tablets / Vocinti® (Walker®) reference preparation) of Takeda Pharmaceutical Company Limited in healthy subjects in the fasting and postprandial states, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To observe the safety and tolerability of the test preparation and the reference preparation in healthy Chinese subjects through changes in adverse event incidence, laboratory test results, vital signs and physical examinations.

Main objective: To study the relative bioavailability of a single oral dose of one metformin empagliflozin tablet (test preparation, specification: each tablet contains 500 mg of metformin hydrochloride and 5 mg of empagliflozin) produced by Beijing Kanglisheng Pharmaceutical Technology Development Co., Ltd. and one original metformin empagliflozin tablet (Ⅰ) produced by Boehringer Ingelheim Pty Ltd (reference preparation, Metformin Hydrochloride and Empagliflozin Tablets (Ⅰ)/Synjardy®/Oushuangjing®, specification: each tablet contains 500 mg of metformin hydrochloride and 5 mg of empagliflozin) in healthy subjects in fasting and postprandial states, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To observe the safety and tolerability of the test preparation and the reference preparation in healthy Chinese subjects through changes in adverse event incidence, laboratory test results, vital signs and physical examinations.